Log in to save to my catalogue

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_02528435v1

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Patients with advanced non–small-cell lung cancer with a PD-L1 expression level of 1% or more of tumor cells were randomly assigned to receive nivolumab plus ipilimumab, nivolumab alone, or chemotherapy. Overall survival was significantly longer among the patients who received nivolumab plus ipilimumab than among those who received chemotherapy.

Alternative Titles

Full title

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_hal_primary_oai_HAL_hal_02528435v1

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_02528435v1

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1910231

How to access this item